683 Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

683 Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-125,000	Closed	-$1.2M	–	164
2018 Q1	$1.2M	Sell	125,000 -425,000	-77%	-$4.58M	0.11%	92
2017 Q4	$4.97M	Sell	550,000 -210,233	-28%	-$1.55M	0.42%	65
2017 Q3	$4.37M	Sell	760,233 -39,767	-5%	-$145K	0.46%	56
2017 Q2	$2.54M	Hold	800,000	–	–	0.37%	62
2017 Q1	$2.72M	Buy	800,000 +80,550	+11%	+$227K	0.42%	56
2016 Q4	$2.07M	Buy	719,450 +369,450	+106%	+$1.31M	0.15%	82
2016 Q3	$2.06M	Buy	+350,000	New	+$1.23M	0.22%	63

Other funds holding DRNA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

683 Capital Management's DRNA Position: Q2 2018 in Review

683 Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2018, closing a stake of 125,000 shares — an estimated $1.2M sold.

683 Capital Management first reported a position in DRNA in Q3 2016 and held it in 7 quarters. The position peaked at $4.97M in Q4 2017. 85 funds tracked by Wall St. Rank hold DRNA as of Q2 2018.

683 Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
683 Capital Management sold 125,000 Dicerna Pharmaceuticals, Inc. shares in Q2 2018, an estimated $1.2M.
683 Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2016 and held it in 7 quarters.
683 Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $4.97M in Q4 2017.
85 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2018.

Based on 683 Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.